TEVA-CHLORPROMAZINE TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE)

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

N05AA01

INN (Tên quốc tế):

CHLORPROMAZINE

Liều dùng:

100MG

Dạng dược phẩm:

TABLET

Thành phần:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 100MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100/500/1000

Loại thuốc theo toa:

Prescription

Khu trị liệu:

PHENOTHIAZINES

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0106167002; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2011-03-08

Đặc tính sản phẩm

_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 1 of 18_
PRODUCT MONOGRAPH
PR
TEVA-CHLORPROMAZINE
Chlorpromazine Hydrochloride Tablets
25 mg, 50 mg and 100 mg
Teva Standard
Antipsychotic–Antiemetic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Date of Preparation:
December 11, 2012
SUBMISSION CONTROL NO: 154593
_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 2 of 18_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
REFERENCES
..............................................................